Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 18, 2024 -- For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study published online Nov. 13 in the New England Journal of Medicine.
Ania M. Jastreboff, M.D., Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues performed a phase 3, double-blind trial involving 2,539 participants with obesity (1,032 of whom also had prediabetes), who were randomly assigned to receive tirzepatide at a once-weekly dose of 5, 10, or 15 mg or placebo in a 1:1:1:1 ratio. The current analysis included the participants with obesity and prediabetes who received tirzepatide or placebo for 176 weeks followed by an off-treatment period of 17 weeks.
The researchers found that the mean percentage change in body weight at 176 weeks was −12.3, −18.7, and −19.7 percent for those receiving 5-, 10-, and 15-mg tirzepatide doses, respectively, compared with −1.3 percent for those receiving placebo. Receipt of a diagnosis of type 2 diabetes occurred in fewer participants in the tirzepatide groups versus the placebo group (1.3 versus 13.3 percent; hazard ratio, 0.07). After 17 weeks off treatment, 2.4 and 13.7 percent of those who received tirzepatide and placebo, respectively, had type 2 diabetes (hazard ratio, 0.12). Apart from COVID-19, the most common adverse events were gastrointestinal, most of which were mild-to-moderate in severity.
"Tirzepatide therapy resulted in sustained weight reduction that was accompanied by a markedly lower risk of progression to type 2 diabetes than that with placebo," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Metformin Beneficial for Osteoarthritis Knee Pain in Overweight, Obesity
THURSDAY, May 1, 2025 -- For patients with overweight or obesity and symptomatic knee osteoarthritis, metformin is associated with a greater improvement in knee pain than placebo...
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.